Characteristics of Patients With Pro-B ALL and t(4;11) and/or MLL-AF-4 Rearrangements Ordered by Age
| Patient No. . | Age (yr) . | WBC (×109/L) . | Karyotype . | MLL-AF-4 . | CD24* . | CD65s* . |
|---|---|---|---|---|---|---|
| 1 | 22 | 16.8 | 46, XY, t(4;11)(q21;q23) | R | 24 | 50 |
| 2 | 22 | 146.0 | 46, XY, t(4;11)(q21;q23) | ND | 29 | 40 |
| 3 | 24 | 562.0 | 45, XY, der(2q) | R | 1 | 8 |
| 4 | 24 | 11.6 | 46, XY, t(4;11)(q21;q23) | R | 3 | 20 |
| 5 | 24 | 373.0 | 46, XY, t(4;11)(q21;q23) | ND | 4 | 30 |
| 6 | 24 | 184.0 | 46, XY, t(4;11)(q21;q23) | R | 17 | 37 |
| 7 | 25 | 198.0 | ND | R | 20 | 30 |
| 8 | 25 | 346.0 | 46, XY, t(4;11)(q21;q23) | ND | 10 | 70 |
| 9 | 26 | 0.8 | ND | R | 20 | 9 |
| 10 | 28 | 355.0 | 46, XX, t(4;11)(q21;q23) | ND | 23 | 17 |
| 11 | 28 | 175.0 | 46, XY, t(4;11)(q21;q23) | ND | 26 | 17 |
| 12 | 30 | 228.0 | 46, XX, t(4;11)(q21;q23) | R | 2 | 45 |
| 13 | 30 | 246.9 | 46, XY, t(4;11)(q21;q23) | R | 9 | 25 |
| 14 | 31 | 168.5 | 46, XY, t(4;11)(q21;q23), i(7)(q10) | R | 7 | 30 |
| 15 | 36 | 67.0 | Normal | R | 0 | 83 |
| 16 | 40 | 11.0 | 46, XX, t(4;11)(q21;q23)/48, XX, t(4;11)(q21;q23), +mar, +mar | ND | 40 | 10 |
| 17 | 41 | 168.0 | 46, XX, t(4;11)(q21;q23) | R | ND | 25 |
| 18 | 49 | 163.0 | 46, XX, t(4;11)(q21;q23) | R | 0 | 46 |
| 19 | 50 | 421.0 | 46, XX, t(4;11)(q21;q23)/48-53, XX, +X, +1, t(4;11)(q21;q23), inc [cp6] | ND | 4 | 74 |
| 20 | 53 | 18.6 | 46, XY, der(4) t(4;11)(q21;q23), der(11) t(11;17)(p11;q11) t(4;11)(q21;q23), −17, +mar | ND | 25 | 2 |
| 21 | 56 | 73.4 | 46, XX, t(4;11)(q21;q23) | ND | 43 | 0 |
| 22 | 62 | 9.4 | 46, XY, t(4;11)(q21;q23) | ND | 44 | 8 |
| Patient No. . | Age (yr) . | WBC (×109/L) . | Karyotype . | MLL-AF-4 . | CD24* . | CD65s* . |
|---|---|---|---|---|---|---|
| 1 | 22 | 16.8 | 46, XY, t(4;11)(q21;q23) | R | 24 | 50 |
| 2 | 22 | 146.0 | 46, XY, t(4;11)(q21;q23) | ND | 29 | 40 |
| 3 | 24 | 562.0 | 45, XY, der(2q) | R | 1 | 8 |
| 4 | 24 | 11.6 | 46, XY, t(4;11)(q21;q23) | R | 3 | 20 |
| 5 | 24 | 373.0 | 46, XY, t(4;11)(q21;q23) | ND | 4 | 30 |
| 6 | 24 | 184.0 | 46, XY, t(4;11)(q21;q23) | R | 17 | 37 |
| 7 | 25 | 198.0 | ND | R | 20 | 30 |
| 8 | 25 | 346.0 | 46, XY, t(4;11)(q21;q23) | ND | 10 | 70 |
| 9 | 26 | 0.8 | ND | R | 20 | 9 |
| 10 | 28 | 355.0 | 46, XX, t(4;11)(q21;q23) | ND | 23 | 17 |
| 11 | 28 | 175.0 | 46, XY, t(4;11)(q21;q23) | ND | 26 | 17 |
| 12 | 30 | 228.0 | 46, XX, t(4;11)(q21;q23) | R | 2 | 45 |
| 13 | 30 | 246.9 | 46, XY, t(4;11)(q21;q23) | R | 9 | 25 |
| 14 | 31 | 168.5 | 46, XY, t(4;11)(q21;q23), i(7)(q10) | R | 7 | 30 |
| 15 | 36 | 67.0 | Normal | R | 0 | 83 |
| 16 | 40 | 11.0 | 46, XX, t(4;11)(q21;q23)/48, XX, t(4;11)(q21;q23), +mar, +mar | ND | 40 | 10 |
| 17 | 41 | 168.0 | 46, XX, t(4;11)(q21;q23) | R | ND | 25 |
| 18 | 49 | 163.0 | 46, XX, t(4;11)(q21;q23) | R | 0 | 46 |
| 19 | 50 | 421.0 | 46, XX, t(4;11)(q21;q23)/48-53, XX, +X, +1, t(4;11)(q21;q23), inc [cp6] | ND | 4 | 74 |
| 20 | 53 | 18.6 | 46, XY, der(4) t(4;11)(q21;q23), der(11) t(11;17)(p11;q11) t(4;11)(q21;q23), −17, +mar | ND | 25 | 2 |
| 21 | 56 | 73.4 | 46, XX, t(4;11)(q21;q23) | ND | 43 | 0 |
| 22 | 62 | 9.4 | 46, XY, t(4;11)(q21;q23) | ND | 44 | 8 |
Abbreviations: R, rearranged; ND, not done.
Percentage of positive lymphoblasts.